Guangzhou Bintie Biotechnology

Guangzhou Bintie Biotechnology is a clinical-stage biopharmaceutical company headquartered in Guangzhou, China, specializing in the development of innovative CAR-T and TCR-T cell therapies for solid tumors. The company utilizes its proprietary Bintie platform to engineer T-cells with enhanced infiltration and persistence capabilities, specifically designed to overcome the immunosuppressive nature of the tumor microenvironment. Its lead candidate, BT-001, is a GPC3-targeted CAR-T therapy currently in Phase 1 clinical development for advanced hepatocellular carcinoma. Bintie is also advancing a pipeline of candidates targeting Claudin 18.2 and other solid tumor antigens, aiming to provide effective treatment options for patients with gastrointestinal and other refractory cancers.